
About MediciNova
MediciNova is a publicly listed company based in San Diego (United States) founded in 2000 by Yuichi Iwaki. Small-molecule therapeutics are developed for asthma, COPD, and neurologic diseases. MediciNova has raised $83.94 million across 5 funding rounds from investors including Sumitomo Mitsui Banking Corporation, CDIB Capital Group and Dr.Ci:Labo. The company has 13 employees. MediciNova has completed 2 acquisitions, including AviGen and Aviagen. Its chief executive, as recorded, is Yuichi Iwaki. Its focus areas include Life Sciences, Pulmonology, Drugs and COPD and Asthma. Its competitors include TFF Pharmaceuticals, Theravance Biopharma and Elastrin; 2 of its 3 listed competitors have raised funding.
Company details
MediciNov is a biopharmaceutical company that develops novel, small-molecule therapeutics for the treatment of diseases with unmet needs. It holds rights to a diversified portfolio of clinical and preclinical product candidates. Their pipeline includes six clinical-stage compounds for the treatment of acute exacerbations of asthma, COPD exacerbations, multiple sclerosis, and other neurologic conditions, asthma, interstitial cystitis, solid tumor cancers, Generalized Anxiety Disorder, preterm labor, and urinary incontinence and two preclinical-stage compounds for the treatment of thrombotic disorders. Focusing on its two prioritized product candidates, MN-221, for the treatment of acute exacerbations of asthma and chronic obstructive pulmonary disease exacerbations, and ibudilast (MN-166AV411).
- Headquarters San Diego, United States
- Employees 13
- Founders Yuichi Iwaki
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website medicinova.com
- Social LinkedIn
- Legal Name Medicinova, Inc.
- Annual Revenue$409.66 K (USD)as on Dec 31, 2025
- Net Profit-$12 M (USD)-8.58as on Dec 31, 2025
- EBITDA-$13.09 M (USD)-3.44as on Dec 31, 2025
- Total Equity Funding$83.94M (USD)
in 5 rounds
- Latest Funding Round$20M (USD), Post-IPO
Jan 2021
- InvestorsSumitomo Mitsui Banking Corporation
& 14 more
- Employee Count13
- Investments & AcquisitionsAviGen
& 1 more
Funding Insights of MediciNova
MediciNova has successfully raised a total of $83.94M across 5 strategic funding rounds. The most recent funding activity was a Post-IPO round of $20 million completed in January 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $83.94M
- Total Rounds 5
- Last Round Post-IPO β $20M
- First Round $10M
(Jun 2000)
- Investors Count 15
All 5 funding rounds of MediciNova with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2021 | $20M | Post-IPO | β | β | |
| Aug 2012 | $1M | Post-IPO | β | β | |
| Sep 2004 | $44.82M | Series C | β | β | |
| Jun 2004 | $29.12M | Series B | β | β | |
| Jun 2000 | $10M | Series A | β | β | β |
15 investors in total: 15 institutional.
Investors in MediciNova
MediciNova has secured backing from 15 investors, including institutional and venture fund investors. Prominent investors backing the company include Sumitomo Mitsui Banking Corporation, CDIB Capital Group and Dr.Ci:Labo.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| aspirecapital.com | ||||
| aquarimco.com | ||||
Sector-agnostic investments are made in early-stage Asia Pacific startups. | 1959 | cdibcapitalgroup.com | Taipei, Taiwan | |
VC firm investing in Japan and the US | nvcc.co.jp | Chiyoda City, Japan | ||
Seed and Early stage VC firm investing in Japan | ut-ec.co.jp | Tokyo, Japan | ||
Growth-stage healthcare companies are invested in by EW Healthcare Partners. | ewhealthcare.com | New York, United States | ||
| poscobioventures.com | ||||
Online slot gaming services are offered by ng24h platform. | nifventures.com | |||
Japan-focused firm for opportunistic value investing and portfolio management strategies. | 2015 | 3dipartners.com | Singapore, Singapore | |
| mizuho-sc.com |
Investor details for MediciNova
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of MediciNova
1 people are tracked at MediciNova (1 in leadership); the tracked headcount is 13.
| Name | Role | Group |
|---|---|---|
Yuichi Iwaki | Founder & CEO | Leadership |
Complete people profiles for MediciNova
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of MediciNova
MediciNova is a publicly listed company on the NASDAQ with ticker symbol MNOV in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date16 Jul 2013
- Listed onTSE: 4875
- Listed entityMediciNova, Inc.
- Exchange sectorHealth technology
- ISINUS58468P2065
- Share price$1.50 (-2.6% on the day) · 2026-10-13
- Market capitalisation$73.8M
- EPS (diluted, trailing year)$-0.22
- Volume (last session)34,800
Financials of MediciNova
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $409,660 | -$12.0M | -$13.1M |
| 2024 | -$11.1M | -$12.7M | |
| 2023 | $1.0M | -$8.6M | -$9.9M |
| 2022 | -$14.1M | -$14.4M | |
| 2021 | $4.0M | -$10.1M | -$10.2M |
Detailed financial statements for MediciNova
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by MediciNova
MediciNova has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include AviGen and Aviagen.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Gene therapy products are developed for inherited and acquired diseases. | avigen.com | Alameda, United States | 1992 | Feb 2009 | $37M | |
Poultry breeding stock is supplied globally by Aviagen. | aviagen.com | Huntsville, United States | 1923 | Dec 2008 | β’β’β’β’ |
Complete acquisition details for MediciNova
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of MediciNova
6 dated milestones of MediciNova across 21 years, from founding to its latest funding, stage changes and deals.
Competitors of MediciNova
MediciNova has 3 listed competitors in our database, 2 of them funded. They include TFF Pharmaceuticals, Theravance Biopharma and Elastrin.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| tffpharma.com | 2018 | Austin, United States | $22.17M | 15 | Developer of inhalation products for chronic respiratory diseases | |
| theravance.com | 2001 | Francisco, United States | 99 | Therapeutics for inflammatory and immunological diseases are developed. | ||
| elastrin.com | 2017 | Simpsonville, United States | $17.25M | Developer of therapeutic targets related to arterial and lung diseases |
Detailed competitors of MediciNova
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of MediciNova
The website of MediciNova (medicinova.com) receives about 3.5K visits a month and ranks #5,782,921 among all websites worldwide, #6,248 in Biotechnology and Pharmaceuticals.
- Monthly visits3.5K
▲ 21% vs previous month
- Unique visitors1.2K
per month
- Global rank#5,782,921
among all websites
- Category rank#6,248
Health · Biotechnology and Pharmaceuticals
- Bounce rate46%
- Pages per visit1.6
- Average visit34 sec
- DevicesDesktop 38% Β· Mobile 62%
Websites whose visitors overlap most with MediciNova. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| medincell.com | 100% | 8.5K | #1,508,006 | View details | |
| debiopharm.com | 98% | 15.1K | #1,818,608 | View details | |
| cambrex.com | 97% | 35K | #883,665 | View details | |
| pelotontherapeutics.com | 96% | View details | |||
| mabvax.com | 95% | View details | |||
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
All 14 similar websites and full traffic analytics for MediciNova
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 14 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Pulmonology
3 companies that operate in the same segment as MediciNova (Pulmonology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of novel protein-based therapeutics using machine learning and biological engineering | 2018 | Somerville, Massachusetts, United States | USD 693 M | 329 | ||
Portable oxygen concentrators are supplied for respiratory therapy needs. | 2001 | Goleta, California, United States | USD 51.65 M | USD 348.67 M | 766 | |
Robotic microsurgical systems for endoscopy are developed. | 2007 | Redwood City, California, United States | USD 733.62 M | 91 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Medicinova
Complete news archive for MediciNova
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about MediciNova
MediciNova was founded in 2000.
MediciNova is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Yuichi Iwaki is the CEO of MediciNova, as recorded in our data. They have also founded this company.
MediciNova is a funded company, having raised a total of $83.94M across 5 funding rounds to date. The company's 1st funding round was a Series A of $10M, raised on Jun 2000.
MediciNova has 13 employees.
Annual revenue of MediciNova is $409.66K as on Dec 31, 2025.
MediciNov is a biopharmaceutical company that develops novel, small-molecule therapeutics for the treatment of diseases with unmet needs. It holds rights to a diversified portfolio of clinical and preclinical product candidates. Their pipeline includes six clinical-stage compounds for the treatment of acute exacerbations of asthma, COPD exacerbations, multiple sclerosis, and other neurologic conditions, asthma, interstitial cystitis, solid tumor cancers, Generalized Anxiety Disorder, preterm labor, and urinary incontinence and two preclinical-stage compounds for the treatment of thrombotic disorders. Focusing on its two prioritized product candidates, MN-221, for the treatment of acute exacerbations of asthma and chronic obstructive pulmonary disease exacerbations, and ibudilast (MN-166AV411).
MediciNova's top competitors include TFF Pharmaceuticals, Theravance Biopharma and Elastrin.
Yes, MediciNova is publicly traded on NASDAQ under the ticker symbol MNOV.
MediciNova has 15 investors. Key investors include Sumitomo Mitsui Banking Corporation, CDIB Capital Group, Dr.Ci:Labo, 3D Investment Partners, and Aspire Capital.
